High Tide Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
High Tide's earnings have been declining at an average annual rate of -18.6%, while the Pharmaceuticals industry saw earnings growing at 46% annually. Revenues have been growing at an average rate of 45.7% per year.
Anahtar bilgiler
-18.6%
Kazanç büyüme oranı
25.8%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 23.1% |
| Gelir büyüme oranı | 45.7% |
| Özkaynak getirisi | -20.9% |
| Net Marj | -6.0% |
| Son Kazanç Güncellemesi | 31 Jul 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
High Tide Inc.'s (CVE:HITI) Shares Leap 30% Yet They're Still Not Telling The Full Story
Oct 19
Does High Tide (CVE:HITI) Have A Healthy Balance Sheet?
Oct 04Market Cool On High Tide Inc.'s (CVE:HITI) Revenues
Aug 14Here's What Analysts Are Forecasting For High Tide Inc. (CVE:HITI) After Its Second-Quarter Results
Jun 16High Tide (CVE:HITI) Seems To Use Debt Quite Sensibly
Apr 25High Tide Inc. (CVE:HITI) Screens Well But There Might Be A Catch
Mar 16Here's Why High Tide (CVE:HITI) Can Afford Some Debt
Sep 23Take Care Before Diving Into The Deep End On High Tide Inc. (CVE:HITI)
Jul 25Does High Tide (CVE:HITI) Have A Healthy Balance Sheet?
Mar 31Is High Tide (CVE:HITI) A Risky Investment?
Nov 16High Tide (CVE:HITI) Is Making Moderate Use Of Debt
Apr 12Gelir ve Gider Dağılımı
High Tide nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Jul 24 | 511 | -30 | 98 | 0 |
| 30 Apr 24 | 504 | -34 | 99 | 0 |
| 31 Jan 24 | 498 | -36 | 99 | 0 |
| 31 Oct 23 | 488 | -39 | 101 | 0 |
| 31 Jul 23 | 469 | -62 | 104 | 0 |
| 30 Apr 23 | 440 | -61 | 101 | 0 |
| 31 Jan 23 | 403 | -68 | 97 | 0 |
| 31 Oct 22 | 357 | -72 | 91 | 0 |
| 31 Jul 22 | 302 | -22 | 82 | 0 |
| 30 Apr 22 | 255 | -21 | 75 | 0 |
| 31 Jan 22 | 215 | -25 | 65 | 0 |
| 31 Oct 21 | 181 | -34 | 54 | 0 |
| 31 Jul 21 | 152 | -32 | 42 | 0 |
| 30 Apr 21 | 128 | -27 | 33 | 0 |
| 31 Jan 21 | 108 | -19 | 28 | 0 |
| 31 Oct 20 | 83 | -6 | 23 | 0 |
| 31 Jul 20 | 70 | -20 | 28 | 0 |
| 30 Apr 20 | 54 | -28 | 28 | 0 |
| 31 Jan 20 | 40 | -26 | 29 | 0 |
| 31 Oct 19 | 31 | -26 | 29 | 0 |
| 31 Jul 19 | 22 | -15 | 22 | 0 |
| 30 Apr 19 | 16 | -12 | 17 | 0 |
| 31 Jan 19 | 11 | -9 | 12 | 0 |
| 31 Oct 18 | 9 | -5 | 7 | 0 |
| 31 Jul 18 | 9 | -1 | 5 | 0 |
| 31 Oct 17 | 10 | 0 | 4 | 0 |
| 31 Oct 16 | 8 | 1 | 3 | 0 |
Kaliteli Kazançlar: HITI is currently unprofitable.
Büyüyen Kar Marjı: HITI is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: HITI is unprofitable, and losses have increased over the past 5 years at a rate of 18.6% per year.
Büyüme Hızlandırma: Unable to compare HITI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: HITI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Özkaynak Getirisi
Yüksek ROE: HITI has a negative Return on Equity (-20.87%), as it is currently unprofitable.